Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

/in

Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX model Data provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme […]

Read more

REDUCED secures EUR 6 million financing led by Novo Holdings to scale its natural food ingredients business

/in

REDUCED, a Copenhagen-based company that uses fermentation technology to transform food and agriculture industry side streams into natural food ingredients, today announced it has secured EUR 6 million in new financing. The funds were raised from a range of investors, including new investment from Novo Holdings and the Nordic flavour house Einar Willumsen, as well […]

Read more

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

/in

PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – SimBioSys, a leading innovator in precision oncology, and General […]

Read more

2023 Novo Holdings Asia Investments Annual Review/Business Update

/in

· Increasing momentum as we expanded our portfolio of investments, built the team and fostered new partnerships · Three new portfolio company investments and two existing portfolio company financing extensions · First ever Novo Nordisk and Novo Holdings Partnering Day focusing on Cardio Metabolic disease Copenhagen, Denmark, 3 April 2024 – Novo Holdings Asia Investments team today publishes its […]

Read more

Vicore Announces Presentations at the 2024 American Thoracic Society International Conference

/in

Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF Additional presentations include preclinical and translational data reflecting the potency of buloxibutid’s upstream mechanism of action as well as the design of the upcoming Phase 2b ASPIRE trial Vicore also to […]

Read more